Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study.
Pizzuti L, Marchetti P, Natoli C, Gamucci T, Santini D, Scinto AF, Iezzi L, Mentuccia L, D'Onofrio L, Botticelli A, Moscetti L, Sperati F, Botti C, Ferranti F, Buglioni S, Sanguineti G, Di Filippo S, di Lauro L, Sergi D, Catenaro T, Tomao S, Giordano A, Maugeri-Saccà M, Barba M, Vici P.
Pizzuti L, et al. Among authors: ferranti f.
Sci Rep. 2017 Sep 6;7(1):10597. doi: 10.1038/s41598-017-10061-2.
Sci Rep. 2017.
PMID: 28878375
Free PMC article.
Clinical Trial.